Financials data is unavailable for this security.
View more
Year on year Aarey Drugs and Pharmaceuticals Ltd had revenues fall -5.57% from 4.19bn to 3.96bn, though the company grew net income 24.20% from 37.71m to 46.84m.
| Gross margin | 2.99% |
|---|---|
| Net profit margin | 1.38% |
| Operating margin | 0.54% |
| Return on assets | -- |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in INRView more
In 2024, Aarey Drugs and Pharmaceuticals Ltd increased its cash reserves by 125.90%, or 8.89m. Cash Flow from Financing totalled 55.85m or 1.41% of revenues. In addition the company used 29.94m for operations while cash used for investing totalled 17.02m.
| Cash flow per share | 3.16 |
|---|---|
| Price/Cash flow per share | 22.82 |
| Book value per share | -- |
|---|---|
| Tangible book value per share | -- |
More ▼
Balance sheet in INRView more
| Current ratio | -- |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | -- |
More ▼
Growth rates in INR
Year on year, growth in earnings per share excluding extraordinary items increased 23.69%. Additionally, five year annualized earnings per share growth ranks below the industry average relative to its peers.
| EPS growth(5 years) | -8.01 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 51.73 |
